Circulating biomolecules identify patients with atrial fibrillation at high risk of cardiovascular events

An analysis of the biomolecule substudy of the EAST – AFNET 4 trial revealed: biomolecule concentrations in the blood of patients with atrial fibrillation can be used to identify patients at high and low cardiovascular risk. Today the findings were presented by Prof. Larissa Fabritz, University Medical Center Hamburg Eppendorf, Hamburg, Germany, at the Frontiers in CardioVascular Biomedicine Congress in Amsterdam and published in Cardiovascular Research (1).

Quelle: IDW Informationsdienst Wissenschaft